Combination of Human Fas (CD95/Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response

The prognosis of hepatocellular carcinoma (HCC) is poor, even with the combined treatment of curative resection and adjuvant chemoradiotherapy. To solve this problem, many biologic therapies have been investigated. Fas ligand (FasL, CD95L) is mainly expressed in activated T lymphocytes and natural k...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liu, Zhongchen, Liu, Ruizhen, Qiu, Jinhua, Yin, Ping, Luo, Fanghong, Su, Jinhua, Li, Wenzhu, Chen, Caixia, Fan, Xin, Zhang, Jiakai, Zhuang, Guohong
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4003059/
https://ncbi.nlm.nih.gov/pubmed/19567199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cmi.2009.23
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados